Anonymous ID: 0af630 Dec. 22, 2018, 10:05 a.m. No.4426065   🗄️.is 🔗kun   >>6428

Brett McGurk, top U.S. envoy in ISIS fight, resigns

 

Brett McGurk, special presidential envoy for the Global Coalition to Defeat ISIS, had been planning to exit his post in February 2019. But sources tell CBS News that he informed Secretary of State Mike Pompeo that he will accelerate his departure due to a strong disagreement with President Trump's snap decision to withdraw 2,000 U.S. troops from Syria, effectively abandoning U.S. allies in the region.

 

McGurk submitted his resignation on Friday, just one day after Defense Secretary James Mattis quit his post citing fundamental disagreements with the commander-in-chief – including one over the importance of honoring U.S. alliances.

 

https://www.cbsnews.com/news/brett-mcgurk-top-u-s-envoy-in-isis-fight-to-quit/

Anonymous ID: 0af630 Dec. 22, 2018, 10:33 a.m. No.4426403   🗄️.is 🔗kun   >>6582 >>6740 >>6750

Pediatric leukemia 'super drug' could be developed in the coming years

 

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.

 

When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia "super drug" to test on humans in a clinical trial.

 

The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.

 

"These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients," said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern's Simpson Querrey Center for Epigenetics. "This is a monster cancer that we've been dealing with for many years in children."

 

https://medicalxpress.com/news/2018-12-pediatric-leukemia-super-drug-years.html